Ticker
ABSI

Price
3.35
Stock movement down
-0.04 (-1.18%)
Company name
Absci Corp
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
309.52M
Ent value
248.64M
Price/Sales
91.71
Price/Book
1.06
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-54.61%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2023-02-03

DIVIDENDS

ABSI does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales91.71
Price to Book1.06
EV to Sales73.67

FINANCIALS

Per share

Loading...
Per share data
Current share count92.39M
EPS (TTM)-1.21
FCF per share (TTM)-1.14

Income statement

Loading...
Income statement data
Revenue (TTM)3.38M
Gross profit (TTM)-3.28M
Operating income (TTM)-111.91M
Net income (TTM)-110.60M
EPS (TTM)-1.21
EPS (1y forward)-1.06

Margins

Loading...
Margins data
Gross margin (TTM)-97.16%
Operating margin (TTM)-3315.94%
Profit margin (TTM)-3277.01%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash107.32M
Net receivables210.00K
Total current assets201.38M
Goodwill21.34M
Intangible assets52.47M
Property, plant and equipment0.00
Total assets339.39M
Accounts payable1.86M
Short/Current long term debt22.14M
Total current liabilities30.03M
Total liabilities46.45M
Shareholder's equity292.94M
Net tangible assets240.48M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-79.85M
Capital expenditures (TTM)23.93M
Free cash flow (TTM)-103.78M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-37.75%
Return on Assets-32.59%
Return on Invested Capital-36.15%
Cash Return on Invested Capital-33.92%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open3.40
Daily high3.63
Daily low3.31
Daily Volume533K
All-time high30.29
1y analyst estimate12.00
Beta-
EPS (TTM)-1.21
Dividend per share-
Ex-div date-
Next earnings date21 Mar 2023

Downside potential

Loading...
Downside potential data
ABSIS&P500
Current price drop from All-time high-88.94%-13.68%
Highest price drop-93.40%-56.47%
Date of highest drop27 Dec 20229 Mar 2009
Avg drop from high-74.60%-11.49%
Avg time to new high65 days13 days
Max time to new high380 days1805 days
COMPANY DETAILS
ABSI (Absci Corp) company logo
Marketcap
309.52M
Marketcap category
Small-cap
Description
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Employees
211
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
In this article, we will discuss the 10 penny stocks that will make you a millionaire. If you want to explore similar stocks, you can also take a look at 5 Penny Stocks That Will Make You A Millionair...
January 10, 2023
The discovery could reduce the time it takes to get new drug candidates to clinic to 18-24 months from six years.
January 10, 2023
This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic Creating antibodies in silico with generative AI represents a major i...
January 10, 2023
VANCOUVER, Wash. and NEW YORK, Jan. 08, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
January 8, 2023
It's not a secret that every investor will make bad investments, from time to time. But it should be a priority to...
December 29, 2022
VANCOUVER, Wash. and NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
November 23, 2022
VANCOUVER, Wash. and NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
November 17, 2022
The company continued to lose money but its CEO says it has enough cash to sustain it through the end of 2025.
November 9, 2022
Absci Corporation (ABSI) delivered earnings and revenue surprises of -11.11% and 32.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
November 9, 2022
Milestone achievement and progress continues in previously announced Merck collaboration Further strengthened executive leadership and Board of Directors VANCOUVER, Wash. and NEW YORK, Nov. 09, 2022 (...
November 9, 2022
Next page